Pricing and Market Access

Analyst Comment

The European Market Access Lag: 2021–2024

GlobalData reviewed the number of branded medicines whose first reimbursement date fell between 2021 and 2024 in each European market.

Analyst Comment

Trump revives plan for IRP use in US via MFN executive order

Partner Content

Next-generation targeting for evolving HCP engagement

News

Pharma faces 30-day deadline under Trump’s pricing order

News

Trump to sign order tying US drug prices to global rates

Analyst Comment

5EU Q1 2024 versus 2025: Pricing shifts, HTA outcomes, and innovative drug trends

Analyst Comment

First two medicinal products to undergo EU joint clinical assessments announced

Features

IRA holds the scope to shape pharma’s research strategy, say experts

Analyst Comment

International Reference Pricing (IRP) 2024: A year in review

Analyst Comment

Vietnam eases foreign investment restrictions in amended pharmaceutical law

Analyst Comment

Key pharma launch trends in 2024

Analyst Comment

All change in Germany – confidential pricing in, IRP out

News

MHRA launches refreshed ILAP to speed up NHS drug access

News

Novo Nordisk’s Ozempic named in latest Medicare price negotiations

Analyst Comment

JP Morgan 2025: Almirall updates strategy with focus on medical dermatology

Daniela Morales

Analyst Comment

Pharma to raise prices on more than 250 drugs in the US from January 2025

Analyst Comment

Setback for UK pharma as government sets unexpectedly high VPAG payback rate in 2025

Janet Beal and Alex Watt

Analyst Comment

Denmark’s HTA evolution

Analyst Comment

Navigating medicine pricing in Turkiye: the pharmaceutical Euro exchange rate

Leyla Hasanzadeh

Analyst Comment

Exploring drug shortages in European markets: the causes, analysis, and response

Features

Psoriasis biosimilars and pricing changes herald treatment paradigm disruptions

Analyst Comment

South Korean pricing reform suggests more flexible drug reimbursement negotiations

Analyst Comment

Unresolved clawback issues obstruct Greece’s potential pharmaceutical framework agreement

GlobalData Healthcare

Analyst Comment

Keytruda and Opdivo: a decade review

Analyst Comment

US negotiations for first round of drugs reveal $6bn in Medicare savings

Analyst Comment

Colombia’s president signs law to strengthen pharmaceutical sector

Daniela Morales

Analyst Comment

Casgevy: Launch sequence and price analysis of the first marketed CRISPR therapy

Analyst Comment

The US Biosecure Act threatens to destabilise the pharmaceutical industry

Analyst Comment

UK’s antibiotic subscription funding model – a route to market sustainability?

Analyst Comment

Ukraine: a market access review over two years of war

Analyst Comment

AIFA’s horizon scanning 2024 predictions suggest an influx of ATMPs

Analyst Comment

The privileged status of orphan medicines in Germany

Analyst Comment

India sees insignificant revision to price ceiling in 2024

Leyla Hasanzadeh

Analyst Comment

Lenmeldy becomes world’s most expensive drug

Analyst Comment

Defining the HTA landscape for France and Germany: 2019–2023

Analyst Comment

Panama updates their medicine regulatory system

Daniela Morales

News

HHS advocates for health equity through sickle cell initiative

Analyst Comment

Japan’s FY 2024 pricing reform expected to favour new listed innovative drugs

Sign up to the newsletter: In Brief

I would also like to subscribe to:

Pharma Technology Focus : Focus (monthly)

Thematic Take (monthly)

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close